163 related articles for article (PubMed ID: 37410050)
1. Efficacy, Convenience, and Safety of Calcipotriene-Betamethasone Dipropionate Cream in Skin of Color Patients With Plaque Psoriasis.
Kontzias CL; Curcio A; Gorodokin B; Tissera KA; Feldman SR; Bhatia N; Callender VD; Kircik L
J Drugs Dermatol; 2023 Jul; 22(7):668-672. PubMed ID: 37410050
[TBL] [Abstract][Full Text] [Related]
2. A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream.
Stein Gold L; Green LJ; Dhawan S; Vestbjerg B; Praestegaard M; Selmer J
J Drugs Dermatol; 2021 Apr; 20(4):420-425. PubMed ID: 33852251
[TBL] [Abstract][Full Text] [Related]
3. Pooled Analysis Demonstrating Superior Patient- Reported Psoriasis Treatment Outcomes for Calcipotriene/ Betamethasone Dipropionate Cream Versus Suspension/Gel.
Armstrong A; Pinter A; Selmer J; Præstegaard M; Reich A; Koo J
J Drugs Dermatol; 2022 Mar; 21(3):242-248. PubMed ID: 35254765
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis.
Pinter A; Reich A; Arenberger P; Gold LS; Armstrong A; Iversen L; Praestegaard M; Augustin M
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2327-2335. PubMed ID: 37432045
[TBL] [Abstract][Full Text] [Related]
5. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis.
Pinter A; Green LJ; Selmer J; Praestegaard M; Gold LS; Augustin M;
J Eur Acad Dermatol Venereol; 2022 Feb; 36(2):228-236. PubMed ID: 34628687
[TBL] [Abstract][Full Text] [Related]
6. A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30
Pinter A; Gold LS; Reich A; Green LJ; Praestegaard M; Selmer J; Armstrong AW; Danø A; Dhawan S; Galván J; Stallknecht SE; Trebbien P; Augustin M
J Eur Acad Dermatol Venereol; 2023 Jan; 37 Suppl 1():14-19. PubMed ID: 36546465
[TBL] [Abstract][Full Text] [Related]
7. INDIVIDUAL ARTICLE: Fixed Combination Calcipotriene/Betamethasone (Cal/BDP) Cream: Evaluating the Role of Polyaphron Dispersion (PAD) Technology in Psoriasis Treatment.
Reddy R; Khan S; Kircik L; Armstrong AW
J Drugs Dermatol; 2023 Aug; 22(8):SF381621s5-SF381621s10. PubMed ID: 37556526
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Foam in the Treatment of Psoriasis in Skin of Color.
Liu J; Cices A; Kaufman B; Sanabria-Gonzalez I; Alexis A
J Drugs Dermatol; 2023 Feb; 22(2):165-173. PubMed ID: 36745370
[TBL] [Abstract][Full Text] [Related]
9. Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey.
López Estebaranz JL; Kurzen H; Galván J
J Dermatolog Treat; 2024 Dec; 35(1):2357618. PubMed ID: 38797809
[TBL] [Abstract][Full Text] [Related]
10. Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 Studies.
Stein Gold L; Pinter A; Armstrong A; Augustin M; Arenberger P; Bhatia N; Praestegaard M; Iversen L; Reich A
Dermatol Ther (Heidelb); 2023 Sep; 13(9):2031-2044. PubMed ID: 37490268
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, quality of life, and treatment satisfaction: an indirect comparison of calcipotriol/betamethasone dipropionate cream versus foam for treatment of psoriasis.
Reich A; Selmer J; Galván J; Trebbien P; Pi-Blanque A; Danø A; Stallknecht SE; Bewley A
Curr Med Res Opin; 2022 Sep; 38(9):1521-1529. PubMed ID: 35575759
[TBL] [Abstract][Full Text] [Related]
12. Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review.
Torres T; Galván J; Crutchley N; Praestegaard M; Iversen L; Gisondi P; Carrascosa JM; Halioua B; Bewley A; Pinter A
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2153-2169. PubMed ID: 37740858
[TBL] [Abstract][Full Text] [Related]
13. An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis.
Bewley A; Barker E; Baker H; Green W; Avey B; Pi-Blanque A; Galván J; Trebbien P; Praestegaard M
J Dermatolog Treat; 2022 Dec; 33(8):3191-3198. PubMed ID: 36036596
[TBL] [Abstract][Full Text] [Related]
14. Patient satisfaction and efficacy of calcipotriol plus betamethasone dipropionate gel in plaque psoriasis patients with poor adherence.
Takahashi H; Katayama H; Uwajima Y; Koda M; Sasaki H; Tanito K; Hagiwara M; Matsuo K; Nakagawa H
J Dermatol; 2020 Nov; 47(11):1249-1256. PubMed ID: 32734661
[TBL] [Abstract][Full Text] [Related]
15. Patient Preference for Calcipotriene and Betamethasone Dipropionate Cream Versus Foam for the Topical Treatment of Psoriasis: A Pilot Study.
Kircik C; Kircik L
J Drugs Dermatol; 2023 Mar; 22(3):271-273. PubMed ID: 36877880
[TBL] [Abstract][Full Text] [Related]
16. Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis.
Gorelick J; Cantrell W; Kucera K; Veverka KA; Gooding K
J Drugs Dermatol; 2018 Aug; 17(8):880-884. PubMed ID: 30124727
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.
Kircik LH; Schlesinger TE; Tanghetti E
J Drugs Dermatol; 2020 Sep; 19(9):874-880. PubMed ID: 33026749
[TBL] [Abstract][Full Text] [Related]
18. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial.
White S; Vender R; Thaçi D; Haverkamp C; Naeyaert JM; Foster R; Martinez Escribano JA; Cambazard F; Bibby A
Am J Clin Dermatol; 2006; 7(3):177-84. PubMed ID: 16734505
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis.
Wu JJ; Hansen JB; Patel DS; Nyholm N; Veverka KA; Swensen AR
J Med Econ; 2020 Jun; 23(6):641-649. PubMed ID: 31985301
[No Abstract] [Full Text] [Related]
20. Enhanced Skin Deposition of Betamethasone Dipropionate from a Novel Formulation and Drug Delivery Technology.
Draelos ZD; Draelos MM; Steele F; Georgiou M; Praestegaard M
Dermatol Ther (Heidelb); 2023 Aug; 13(8):1763-1771. PubMed ID: 37351830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
